Table 1.
Overview of cancer samples. Classification of molecular subtypes was based on recommendations of the St Gallen classification system (Goldhirsch et al., 2011). For details, see section 2.3. In addition, rebiopsy samples from four patients were analyzed (Table S3)
| No. of patients with cancer | Subtype class based on IHC (St. Gallen) | Grade | No. of samples for PEA | No. of samples for PAM50 | No. of patients with multiplea samples (n = 2) | No. of patients with multiplea samples (n = 3) |
|---|---|---|---|---|---|---|
| 9b |
Luminal A (LumA) |
I–II | 14 | 6 | 3c | 1 |
| 4 |
Luminal B (LumB) |
II–III | 5 | 4 | 1 | |
| 3 |
Nonluminal HER (HER) |
III | 5 | 5 | 2c | |
| 5 |
Luminal HER (LumHER) |
II–III | 6 | 5 | 1c | |
| 4 |
TNBC (TNB) |
II–III | 4 | 2 | 0 | |
| Total: 25 | 34 | 22 | 7 | 1 |
aSamples from multifocal lesion, one FNA sample per lesion. bTwo of nine patients were diagnosed with lobular cancer. All others had ductal cancers. cIn three patients, samples were obtained from a primary tumor and from axillary metastases.